STOCKS TELEGRAPH

Tag: ARVN

  • Arvinas, Inc. (ARVN) Stock on the Rise Following Global Partnership with Pfizer

    Arvinas, Inc. (ARVN) stock prices were up by 8.68% some time after market trading commenced on July 22nd, 2021, bringing the price per share up to USD$84.28 early on in the trading day.

    Partnership with Pfizer

    July 22nd, 2021 saw the company announce its global collaboration with Pfizer in order to develop and commercialize ARV-471, an investigational oral PROTAC, estrogen receptor protein degrader. The estrogen receptor has been shown to drive diseases in most cases and forms of breast cancer. The treatment is currently in Phase 2 dose expansion clinical trial, designed to treat patients with estrogen receptor (ER) positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-).

    Details of the Agreement

    As per the agreement, the partnering company will make an upfront payment of USD$650 million to ARVN, as well as a USD$350 million equity investment in the company. Global development costs, commercialization expenses, and profits will be split equally between the partnering companies. The combination of the company’s leadership in targeted protein degradation with Pfizer’s global capabilities and extensive expertise in breast cancer is expected to prove transformational.

    Scope of ARV-471

    This, in turn, will substantially enhance and accelerate the development and eventual commercialization of ARV-471 while concurrently advancing the company’s strategy of building a global and integrated biopharmaceutical company. Despite the advancement of the oncology space over recent years, there is still a sizeable unmet need that persists in the treatment of HR+ breast cancer. The partnership with Pfizer will see the deployment of PROTAC technology in a bid to help mitigate the devastation caused by the disease.

    ARV-471’s Potential

    December 2020 saw the company present interim data for its Phase 1 dose-escalation clinical trial of ARV-471 in patients with locally advanced or metastatic ER+/HER2- breast cancer. The treatment is indicated for its potential as a novel oral ER targeted therapy. Patients enrolled in the study were heavily pretreated, having been administered with cyclin-dependent kinase (CDK) 4/6 inhibitors. Despite the extensive pretreatment and the advanced stage of disease, the interim results demonstrated the treatment’s ability to promote substantial ER degradation and exhibits an encouraging clinical efficacy and tolerability profile.

    Future Outlook for ARVN Stock

    Armed with a massively expansive collaboration with Pfizer, the company is keen to make the most of the opportunities afforded to it as it expands and consolidates its market footprint. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal to usher in organic growth over the long term.

  • 32 Stocks Making Sharp Moves in Pre Market Session

    32 Stocks Making Sharp Moves in Pre Market Session

    Sundial Growers Inc. (SNDL) stock soared 1.72% to $0.5088 in the pre-market trading after declaring $50 million prepayment on senior secured non-revolving term credit facility. The most recent rating by CIBC, on August 17, 2020, is a Neutral.

    FuelCell Energy Inc. (FCEL) is up more than 2.09% at $8.31 in pre-market hours Wednesday December 16, 2020. The stock had jumped over 5.71% to $8.14 in the last trading session.

    BioCardia Inc. (NASDAQ: BCDA) shares are trading up 5.22% at $7.05 at the time of writing after reporting that it has entered into definitive agreements with investors for the purchase and sale of 1,789,474 shares of its common stock at a purchase price of $4.75 per share Company’s 52-week ranged between $1.91 to $6.95.

    Before the trading started on December 16, 2020, MicroVision Inc. (MVIS) is down -1.9% to reach $4.13. It has been trading in a 52-week range of $0.15 to $3.45.

    Apartment Investment and Management Company (AIV) tumbled over -6.75% at $4.7 in pre-market trading today following completion of separation of Apartment Income REIT Corp.

    Before the trading started on December 16, 2020, GeoVax Labs Inc. (GOVX) is down -7.86% to reach $3.4. It has been trading in a 52-week range of $2.30 to $60.00.

    Anchiano Therapeutics Ltd. (ANCN), a Biotechnology company, dropped about -7.99% at $2.65 in pre-market trading Wednesday after the company and and Chemomab Ltd. declared their entry into a definitive merger agreement.

    BEST Inc. (NYSE: BEST) shares are trading up 3.29% at $2.2 at the time of writing. Company’s 52-week ranged between $2.36 to $6.54. Analysts have a consensus price target of $3.50.

    Veru Inc. (VERU) stock moved down -7.5 percent to $8.63 in the pre-market trading. The company lately reported positive Phase 2 clinical trial results for Enobosarm.

    Northern Dynasty Minerals Ltd. (NAK) is up more than 3.67% at $0.325 in pre-market hours Wednesday December 16, 2020. The stock had dropped over -4.74% to $0.31 in the last trading session.

    Moderna Inc. (MRNA) stock plunged -3.33% to $142.32 in the pre-market trading. The company recently confirmed supply agreement with the Ministry of Health to supply Singapore with mRNA vaccine against COVID-19 (mRNA-1273). The most recent rating by Needham, on December 09, 2020, is a Hold.

    Before the trading started on December 16, 2020, Teligent Inc. (TLGT) is up 2.2% to reach $0.93. It has been trading in a 52-week range of $0.46 to $6.46.

    HEXO Corp. (HEXO), a Drug Manufacturers – Specialty & Generic company, rose about 2.75% at $1.12 in pre-market trading Wednesday. The firm recently revealed it first quarter fiscal 2021 financial results.

    Gevo Inc. (NASDAQ: GEVO) shares are trading up 4.74% at $1.99 at the time of writing. Company’s 52-week ranged between $0.46 to $2.91.

    Timber Pharmaceuticals Inc. (TMBR) stock moved down -0.97 percent to $1.02 in the pre-market trading after receiving notice of allowance from U.S. Patent and Trademark Office for Lead Asset TMB-001.

    Baidu Inc. (BIDU) is up more than 4.33% at $193.53 in pre-market hours Wednesday December 16, 2020. The stock had jumped over 13.83% to $185.50 in the last trading session.

    Aurora Cannabis Inc. (ACB) gained over 1.76% at $10.39 in pre-market trading Wednesday December 16, 2020 after provided a business update.

    Velodyne Lidar Inc. (VLDR) stock soared 3.91% to $20.2 in the pre-market trading after declaring a sales agreement for Alpha Prime sensors with May Mobility, a pioneer in autonomous vehicle (AV) technology. The most recent rating by Needham, on December 15, 2020, is a Buy.

    Before the trading started on December 16, 2020, Nikola Corporation (NKLA) is up 3.64% to reach $17.08. It has been trading in a 52-week range of $10.29 to $93.99.

    PG&E Corporation (NYSE: PCG) shares are trading up 2.87% at $12.55 at the time of writing after paying over $268 million in property taxes to 50 California counties. Company’s 52-week ranged between $6.25 to $18.34. Analysts have a consensus price target of $15.

    SELLAS Life Sciences Group Inc. (SLS) tumbled over -3.72% at $6.99 in pre-market trading today. The firm recently reported the pricing of $16.2 million registered direct offering.

    Nxt-ID Inc. (NASDAQ: NXTD) shares are trading down -1.66% at $0.4795 at the time of writing. Company’s 52-week ranged between $0.21 to $0.89.

    Qualigen Therapeutics Inc. (QLGN), a Biotechnology company, rose about 1.23% at $4.12 in pre-market trading Wednesday following its announcement of issuance of U.S. Patent for expanded applications of ALAN Anticancer Platform Technology.

    Concord Medical Services Holdings Limited (CCM) lost over -30.32% at $3.7 in pre-market trading Wednesday December 16, 2020.

    Aphria Inc. (APHA) grew over 11.45% at $9.05 in pre-market trading today following its declaration of definitive agreement with Tilray, Inc. (TLRY), to combine their businesses and create the world’s largest global cannabis company.

    Before the trading started on December 16, 2020, Hecla Mining Company (HL) is up 5.9% to reach $5.74. It has been trading in a 52-week range of $1.40 to $6.79.

    Twitter Inc. (TWTR), a Internet Content & Information company, rose about 3.1% at $54.46 in pre-market trading Wednesday after the declaration from the Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (AMZN), that Twitter (TWTR) has selected AWS to provide global cloud infrastructure to deliver Twitter timelines.

    Torchlight Energy Resources Inc. (TRCH) stock plunged -4.63% to $0.5332 in the pre-market trading. The most recent rating by ROTH Capital, on March 13, 2020, is a Neutral.

    Arvinas Inc. (ARVN) is up more than 1.41% at $75.3 in pre-market hours Wednesday December 16, 2020 after reporting the pricing of an underwritten public offering of 5,714,286 shares of its common stock at a price of $70.00 per share, before underwriting discounts and commissions.

    Cinedigm Corp. (CIDM) stock plunged -0.54% to $0.84 in the pre-market trading. The most recent rating by The Benchmark Company, on July 07, 2020, is a Speculative buy.

    PDL BioPharma Inc. (PDLI) grew over 6.59% at $2.75 in pre-market trading today. The company recently reported that it has entered into a Capital Provision Agreement with Epps Investments LLC.

    vTv Therapeutics Inc. (VTVT) is down more than -31.99% at $2.02 in pre-market hours Wednesday December 16, 2020 after revealing that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition as assessed by the 14-item Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-cog14) relative to placebo.

  • Biotech Roundup: Nurse in New York City was first vaccinated against COVID-19

    Biotech Roundup: Nurse in New York City was first vaccinated against COVID-19

    As the U.S. reached 300,000 deaths connected with Covid-19, the first shots were given. The nurse in New York City was first vaccinated against COVID-19. On Monday, during the American mass vaccine drive, the first shot was rendered, which opened a new chapter in the fight against coronavirus’s pandemic.

    This week’s total number of shipments could exceed 2.9 million doses of Pfizer vaccine, which the FDA approved last Friday night for emergency use. A further 2.9 million supplies are eligible three weeks from now for recipients to receive a second dose.

    Phase 3 clinical trials found that the vaccine is 95 percent successful over a spectrum of age, ethnic and racial groups when administered in two doses. The first vaccination this week is obtained by front-line community staff and others who work with long-term care.

    BioCardia Inc. (NASDAQ:BCDA) shares were trading up 58.87% at $4.48 at the time of writing on Monday following the company reported that it has entered into definitive agreements with investors for the purchase and sale of 1,789,474 shares of its common stock at a purchase price of $4.75 per share in a registered direct offering priced at-the-market under Nasdaq rules.

    BioCardia Inc. (NASDAQ:BCDA) share price went from a low point around $1.91 to briefly over $6.75 in past 52 weeks, though shares have since pulled back to $4.48. BCDA market cap has remained high, hitting $60.84M at the time of writing, giving it price-to-sales ratio of more than 200.

    Rubius Therapeutics Inc. (RUBY) last closed at $8.73, in a 52-week range of $3.35 to $14.44. Analysts have a consensus price target of $10.67.

    AnPac Bio-Medical Science Co. Ltd. (ANPC) stock soar by 35.07% to $5.70 after reporting that it has made significant progress in detecting pre-cancer diseases.

    Synlogic Inc. (NASDAQ:SYBX) Shares headed rising, higher as much as 13.39% following the announcement of advancement of SYNB1891 to combination arm dosing with PD-L1 checkpoint inhibitor in the on-going phase 1 study for the treatment of solid tumors and lymphoma. The most recent rating by Oppenheimer, on August 21, 2019, is at a Perform.

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) rose 29.20% after gaining more than $35.33 on Monday.

    Arbutus Biopharma Corporation (ABUS) last closed at $4.88, in a 52-week range of $0.88 to $9.02. Analysts have a consensus price target of $6.40.

    Amarin Corporation plc (AMRN) stock soar by 1.60% to $5.09 after announcing the presentation of important VASCEPA® (icosapent ethyl)-related scientific findings during the National Lipid Association (NLA) Scientific Sessions 2020. The most recent rating by JP Morgan, on September 29, 2020, is at a Neutral.

    Arvinas Inc. (NASDAQ:ARVN) Shares headed rising, higher as much as 95.06% after revealing that it is commencing an underwritten public offering of $250.0 million of its common stock. The most recent rating by Oppenheimer, on December 14, 2020, is at an Outperform.

    BioLineRx Ltd. (NASDAQ:BLRX) rose 26.97% after gaining more than $0.72 on Monday. The company on November 23, 2020 reported its financial results for the quarter ended September 30, 2020.

    Homology Medicines Inc. (FIXX) last closed at $11.97, in a 52-week range of $8.70 to $22.50.

    BioCryst Pharmaceuticals Inc. (BCRX) stock soar by 4.68% to $8.50. The firm is presenting at the JMP Securities Hematology Summit, which is being conducted as a virtual event, on Tuesday, December 15, 2020 at 3:30 p.m. ET. The most recent rating by JP Morgan, on September 29, 2020, is at an Overweight.

    BioNTech SE (NASDAQ:BNTX) Shares headed falling, lower as much as -14.95% after the company and Pfizer Inc. (PFE) declared additional data on neutralizing antibody and T cell responses from the Phase 1/2 trial with BNT162b2 conducted in Germany. The most recent rating by BofA Securities, on December 01, 2020, is at a Neutral.

    Akebia Therapeutics Inc. (NASDAQ:AKBA) rose 10.80% after gaining more than $0.31 on Monday. The firm reported the latest scheduled program of AkebiaShares, a peer-to-peer educational series for the kidney community.

    Seelos Therapeutics Inc. (SEEL) last closed at $1.28, in a 52-week range of $0.42 to $1.71 after announcing the sale of a $12.0 million senior secured convertible note and shares of Seelos common stock to investors.

    VBI Vaccines Inc. (VBIV) stock soar by 6.71% to $3.34. The company recently revealed a partnership for the commercialization of VBI’s 3-antigen prophylactic hepatitis B (HBV) vaccine in the United States, Europe, and Canada, pending regulatory approvals. The most recent rating by Raymond James, on August 27, 2020, is at a Strong buy.